Introduction Studies of bevacizumab and pembrolizumab in the treatment of malignant
pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective
of real-world patients. We aimed to determine the proportion of real-world patients who
would be eligible for trials, identify patients who participated in clinical trials, and examine
treatment and outcome data. Patients and Methods Consecutive patients with unresectable
malignant pleural mesothelioma seen at our center from January 2012 to July 2018 were …